Kiniksa(KNSA) Newsfilter·2025-02-25 12:30Core Insights - Kiniksa Pharmaceuticals reported strong sales growth for ARCALYST, achieving $417.0 million in net product revenue for the full year 2024, a 79% increase year-over-year [2][10] - The company expects ARCALYST net product revenue to reach between $560 million and $580 million in 2025 [2][10] - Kiniksa plans to discontinue the development of abiprubart in Sjögren's Disease and focus on cardiovascular indications [2][7] Financial Performance - Total revenue for Q4 2024 was $122.5 million, compared to $83.4 million in Q4 2023 [10][25] - Full year 2024 total revenue was $423.2 million, up from $270.3 million in 2023 [10][25] - The net loss for Q4 2024 was $8.9 million, compared to a net income of $25.2 million in Q4 2023 [10][25] - For the full year 2024, the net loss was $43.2 million, compared to a net income of $14.1 million in 2023 [10][25] Product Development - Kiniksa is advancing KPL-387 for recurrent pericarditis, with a Phase 2/3 clinical trial expected to start in mid-2025 [2][8][10] - KPL-387 aims to provide a single monthly subcutaneous injection option for patients [2][7] - KPL-1161 is also being developed with a target profile of quarterly subcutaneous dosing [7][9] Market Position - Since the launch of ARCALYST, over 2,850 prescribers have written prescriptions for recurrent pericarditis [7] - As of Q4 2024, approximately 13% of the target 14,000 multiple-recurrence patients were actively on ARCALYST treatment [7]